We raised $103M in our Series C financing, following a series of successful regulatory and commercial milestones. This funding was pivotal in supporting our efforts to expand our portfolio, advance meaningful pharma and biotech partnerships to accelerate biomarker-driven therapies and grow our infrastructure to continue leading global decentralization of comprehensive genomic profiling for cancer.
PLA Code granted for elio™ tissue complete test –April 2, 2021
PGDx pursued and successfully obtained the following Proprietary Laboratory Analyses (PLA) code for the PGDx elio™ tissue complete test:
0250U Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden
This code became effective and is available for use for dates of service on or after July 1, 2021. The national price established by CMS for PLA 0250U will be available on the 2022 Clinical Lab Fee Schedule once it is published online.
elio™ plasma complete liquid biopsy CGP research assay launches – June 01, 2021
The PGDx sample-to-answer kitted liquid biopsy solution analyzes circulating tumor DNA for genomic alterations in cancer. Our 500+ gene assay puts cutting-edge plasma based technology in the hands of scientists researching tumor biomarkers directly from blood samples.
Co-founder Luis Diaz appointed as Member of National Cancer Advisory Board — September 15, 2021
One of our scientific founders, Luis Diaz, was appointed by President Joe Biden as a Member of the National Cancer Advisory Board (NCAB). NCAB plays an important role in guiding the Director of the National Cancer Institute (NCI) in setting the course for the national cancer research program.